NCT01345734 (Lead-Ph) is a clinical trial of liraglutide in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT01345734?

NCT01345734 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT01345734?

Interventions in NCT01345734: liraglutide.

What condition does NCT01345734 study?

NCT01345734 studies Diabetes, Diabetes Mellitus, Type 2.

Is NCT01345734 still recruiting?

NCT01345734 is currently completed. Last updated 11 December 2018.

Last reviewed 2018-12-11 · How we verify

NCT01345734: Lead-Ph

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed Last updated 11 December 2018

What this trial tests

trial testing liraglutide in Diabetes in 1,056 participants. Completed in 26 July 2013.

Timeline

1 September 2011

Primary endpoint
26 July 2013

26 July 2013

Quick facts

Lead sponsor	Novo Nordisk A/S
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,056
Start date	1 September 2011
Primary completion	26 July 2013
Estimated completion	26 July 2013
Sites	1 location across Philippines

Drugs / interventions tested

liraglutide (liraglutide) — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, any sex, with Diabetes or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes.
Jimeno C, Kho S, de Los Santos GK, Buena-Bobis N, et al · · 2018 · PMID 33442116 · DOI 10.15605/jafes.033.02.02

Verify or expand the search:

Other trials of liraglutide

Trials testing the same drug.

NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
NCT05965908 — Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome · Phase 3 · completed
NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
NCT03292185 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec a · Phase 1 · completed
NCT02964247 — LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. · Phase 3 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01345734 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 11 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01345734.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing